Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Aug;80(2):127-128.
doi: 10.1016/j.eururo.2021.03.019. Epub 2021 Mar 29.

Virtual Conferences and the COVID-19 Pandemic: Are We Missing Out with an Online Only Platform?

Affiliations
Editorial

Virtual Conferences and the COVID-19 Pandemic: Are We Missing Out with an Online Only Platform?

Phillip Woodruff et al. Eur Urol. 2021 Aug.

Abstract

Virtual conferences rapidly became the norm during the COVID-19 pandemic. Although necessary, there are shortfalls to strictly virtual meetings, including less enthusiasm for submitting abstracts. An approach that combines in-person attendance and virtual platforms may be an optimal compromise both during the ongoing pandemic and moving forward.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Pie chart depicting results of an @EUplatinum Twitter poll on December 16, 2020 assessing the impact of strictly virtual conferences on the likelihood of submitting research abstracts.

Similar articles

Cited by

References

    1. Achakulvisut T., Ruangrong T., Bilgin I. Improving on legacy conferences by moving online. Elife. 2020;9 doi: 10.7554/eLife.57892. - DOI - PMC - PubMed
    1. Wallis C.J.D., Catto J.W.F., Finelli A. The impact of the COVID-19 pandemic on genitourinary cancer care: re-envisioning the future. Eur Urol. 2020;78:731–742. - PMC - PubMed
    1. Motzer R, Alekseev B, Rha SY, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. doi: 10.1056/NEJMoa2035716. In press. 10.2217/fon-2018-0745. - DOI - PubMed
    1. Powles T., Rosenberg J.E., Sonpavde G.P. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021;384:1125–1135. - PMC - PubMed
    1. Hofman M.S., Emmett L., Sandhu S. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomized, open-label, phase 2 trial. Lancet. 2021;397:797–804. - PubMed

Publication types